[FinanceYahoo] LLY announced that the FDA has expanded the Emergency Use Authorization (EUA) for its cocktail antibody medicine, bamlanivimab plus etesevimab to include the post-exposure prevention (prophylaxis) for COVID-19 indication.
This means the cocktail medicine can now be used (on an emergency basis) to treat certain people who have been exposed to the virus or who are at high risk of exposure in an institutional setting, including a nursing home or prison..
Another in the expanding set of treatments. There are several others. This is one reason why some places with thousands of new cases have only a few fatalities. |